Upadacitinib
Upadacitinib is an orally administered, once-daily selective Janus kinase 1 (JAK1) inhibitor, formulated as an extended-release tablet and classified under ATC code L04.
Upadacitinib is an orally administered, once-daily selective Janus kinase 1 (JAK1) inhibitor, formulated as an extended-release tablet and classified under ATC code L04. JAK enzymes work in pairs beneath cytokine receptors, and which pair a drug blocks determines both what it treats and what it costs the patient: JAK1 partners in the receptors for Interleukin-6 (IL-6), the common gamma-chain cytokine IL-4 and IL-13, and the interferons, whereas JAK2 carries erythropoietin and thrombopoietin signaling. Preferential inhibition of JAK1 is therefore intended to suppress inflammatory signaling while sparing the haematopoietic effects that follow from blocking JAK2 — selectivity that is relative rather than absolute, and narrows as the dose rises. Not every inflammatory cytokine runs through this system: IL-17A signals through its own receptor and the ACT1–NF-κB/MAPK route, outside JAK/STAT entirely.
The drug is approved across a wide range of immune-mediated inflammatory diseases, including rheumatoid and psoriatic arthritis, axial spondyloarthritis, atopic dermatitis in adults and adolescents, ulcerative colitis, Crohn's disease (CD) and giant cell arteritis — a breadth that follows from blocking a signaling node shared by many cytokines rather than a single mediator. Compared with a biologic such as dupilumab, which neutralizes the IL-4 receptor alpha chain, upadacitinib suppresses several cytokine axes at once through an oral agent, which can help in refractory or overlapping phenotypes; compared with the earlier, less selective tofacitinib and baricitinib, its narrower profile is the intended advance.
Breadth of coverage is also the source of risk. Upadacitinib carries the class boxed warnings extrapolated from tofacitinib's cardiovascular outcome trial — serious infection, major adverse cardiovascular events, malignancy and thrombosis — together with herpes zoster reactivation, and laboratory monitoring of blood counts, lipids and liver enzymes is routine. Whether JAK1 selectivity translates into a genuinely better safety profile than first-generation agents remains an open question rather than an established one.
Where the papers sit
20 papers from the last 6 months study upadacitinib directly · updated from PubMed 7 Oct 2026
Study type 5 clinical trials · 6 observational · 3 human data · 6 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Crohn's Disease Treatment
Real-world upadacitinib treatment is being evaluated for difficult-to-treat Crohn's disease, with clinical remission and persistence tracked through 12 and 24 weeks. Multicentre cohorts consistently focus on effectiveness and safety outside trials. Reports of semen discoloration add a patient-reported safety concern, while formulation work addresses bioequivalence. Longer follow-up is still needed to define durability and uncommon adverse effects.
5 papers · 25%
-
Atopic Dermatitis Treatment
Upadacitinib and dupilumab are being compared for durable control of moderate-to-severe atopic dermatitis. Deep improvements in Eczema Area and Severity Index and patient-reported outcomes support sustained benefit with long-term upadacitinib treatment. Real-world response trajectories and structured benefit-risk analyses are moving treatment choice beyond short-term efficacy. Oral microbiome changes are an emerging exploratory outcome rather than a settled mechanism.
5 papers · 25%
-
Ulcerative Colitis Therapies
Advanced therapies for ulcerative colitis are being compared through treatment failure, remission, safety and pharmacokinetic outcomes. Real-world analyses place upadacitinib alongside tofacitinib, filgotinib, adalimumab and infliximab, with upadacitinib showing particularly low treatment-failure risk. East Asian data extend the evidence across regional populations and active disease severity. The main open question is how these comparative results translate into long-term sequencing after corticosteroid or biologic exposure.
3 papers · 15%
-
Others — JAK1 Inhibition Across Diseases
JAK1 inhibition is being tested across rheumatoid arthritis, vitiligo, SAPHO syndrome and refractory immune checkpoint inhibitor colitis, alongside mechanistic safety studies. Evidence ranges from seven-year rheumatoid arthritis outcomes and phase 3 vitiligo trials to small retrospective or salvage reports. Platelet procoagulant responses, microvascular dilation, infection and cardiovascular risk remain important safety questions. CCR7-JAK1 hydrogel targeting illustrates a separate move toward localized combination treatment, but no single clinical direction dominates.
7 papers · 35%
Upadacitinib's safety account must include a recurrent semen-discoloration signal
The Chinese multicentre study of difficult-to-treat Crohn's disease and the South Korean case series of men with inflammatory bowel disease both found blue or green semen during upadacitinib treatment, rather than the largely established safety profile implying no distinctive male reproductive signal; the Chinese study also described a suspected paternal reproductive event, although causality was not established 42693782Sep 42325015Jun. Together, these independent observations make semen discoloration a reproducible potential adverse effect that should be actively recognised and monitored rather than treated as an isolated report.
Upadacitinib is repositioned as a locally delivered component of a precision combination hydrogel
The CCR7-siRNA/upadacitinib pH-responsive hydrogel study in imiquimod-induced psoriasis and DNCB-induced atopic dermatitis mouse models 42237357Jun gives upadacitinib a role not used elsewhere in the set: a topical payload co-delivered with gene-silencing therapy to target both immune-cell chemotaxis and local inflammatory signaling. Instead of functioning as a conventional standalone systemic JAK1 inhibitor, upadacitinib is incorporated into a local combination platform that improved skin lesions, barrier function, inflammatory infiltration, and systemic immune measures in the models.
Papers
The 20 papers from the last 6 months that study upadacitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Crohn's Disease Treatment (5)
- Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Alimentary pharmacology & therapeutics · 10 Sept 2026 PMID 42720163
- Real-world efficacy and safety of upadacitinib in difficult-to-treat Crohn's disease: a 24-week multicenter study from China. Intestinal research · 4 Sept 2026 PMID 42693782
- Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease. Gut and liver · 22 Jun 2026 PMID 42325015
- Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical pharmacology in drug development · 29 May 2026 PMID 42212538
- Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry. United European gastroenterology journal · 30 Apr 2026 PMID 42057704
Atopic Dermatitis Treatment (5)
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study. Dermatology and therapy · 30 Jul 2026 PMID 42533213
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
- Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. The Journal of dermatological treatment · 11 May 2026 PMID 42112622
Ulcerative Colitis Therapies (3)
- Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 29 Sept 2026 PMID 42810421
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of gastroenterology and hepatology · 19 Aug 2026 PMID 42613995
- Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Advances in therapy · 9 May 2026 PMID 42105145
Others — JAK1 Inhibition Across Diseases (7)
- Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International journal of rheumatic diseases · 28 Aug 2026 PMID 42661505
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet (London, England) · 13 Aug 2026 PMID 42594914
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study. Lupus science & medicine · 7 Jul 2026 PMID 42414040
- Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection. BMJ case reports · 6 Jul 2026 PMID 42409426
- Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
- A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases. Journal of nanobiotechnology · 4 Jun 2026 PMID 42237357
By study type
Clinical trials (5)
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies. Journal of gastroenterology and hepatology · 19 Aug 2026 PMID 42613995
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet (London, England) · 13 Aug 2026 PMID 42594914
- Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. RMD open · 24 Jun 2026 PMID 42342288
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
- Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. Clinical pharmacology in drug development · 29 May 2026 PMID 42212538
Observational studies and case reports (6)
- Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients. International journal of rheumatic diseases · 28 Aug 2026 PMID 42661505
- Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study. Lupus science & medicine · 7 Jul 2026 PMID 42414040
- Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection. BMJ case reports · 6 Jul 2026 PMID 42409426
- Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease. Gut and liver · 22 Jun 2026 PMID 42325015
- Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Advances in therapy · 9 May 2026 PMID 42105145
- Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry. United European gastroenterology journal · 30 Apr 2026 PMID 42057704
Human data, design not indexed (3)
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Anti-TNF, pan-JAK, and JAK1-selective inhibition differentially alter mechanisms of flow-mediated dilation in human microvessels. American journal of physiology. Heart and circulatory physiology · 4 Aug 2026 PMID 42552281
- Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. The Journal of dermatological treatment · 11 May 2026 PMID 42112622
Unclassified: not yet indexed with MeSH (6)
- Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 29 Sept 2026 PMID 42810421
- Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Alimentary pharmacology & therapeutics · 10 Sept 2026 PMID 42720163
- Real-world efficacy and safety of upadacitinib in difficult-to-treat Crohn's disease: a 24-week multicenter study from China. Intestinal research · 4 Sept 2026 PMID 42693782
- Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study. Dermatology and therapy · 30 Jul 2026 PMID 42533213
- A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases. Journal of nanobiotechnology · 4 Jun 2026 PMID 42237357
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
Written from 20 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-12 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.